Envista Holdings (NVST) delivered another beat-and-raise quarter, though the top line is clearly slowing. Adjusted EPS of $0.40 topped the $0.35 consensus by 14.3% and rose 25.0% year over year. Revenue of $691.5 million edged past the $686.31 million estimate by 0.8% and grew 3.2%. Management lifted full-year adjusted EPS guidance to $1.54-$1.58 from $1.50-$1.55, the second straight increase. The guide now sits well above the original $1.35-$1.45 range. But the earnings engine is outrunning the sales engine by a widening margin. Core sales growth slowed to 2.7% from 5% in Q2, 9.5% in Q1 and 10.8% in Q4 2025. That is the central tension: margins and guidance keep improving while the growth trajectory keeps weakening.

The headline GAAP figures are distorted. GAAP diluted EPS of $3.11 compared with a $0.18 loss a year ago, but $2.62 of that came from a $428 million gain before tax effects. The gain is non-cash and comes from releasing cumulative translation adjustments as Envista dissolved legal entities. It says nothing about operations, and management excluded it from adjusted results. More relevant is that adjusted figures also stripped out $15.6 million of IEEPA tariff refunds, which makes the adjusted beat cleaner rather than flattered. Even so, the beat had some help:

• **Share count:** adjusted net income rose about 21%, with the lower share count lifting per-share growth to 25%.
• **Tax rate:** the full-year rate fell to roughly 25.5% from an initial 28% assumption, which supports the EPS guide.

Underneath, adjusted gross margin expanded 20 basis points to 56.3%, the third consecutive quarter of improvement. Adjusted EBITDA margin rose 80 basis points to 15.3%. Even so, adjusted EBITDA growth slowed to 9% from 28% in Q2.

The segment split shows where the momentum is concentrated. Equipment & Consumables posted 4.1% core growth, and its adjusted operating margin jumped to 22.4% from 20.1%. Specialty Products & Technologies grew only 2.0%. Its adjusted operating profit was flat at $66.7 million, and its margin slipped to 15.0% from 15.5%. On the call, China was the main drag: the region contracted low double digits, a roughly $7 million net headwind that included about $10 million of orthodontic destocking ahead of volume-based procurement (VBP). Consumables cooled to low single digits from high single digits in the first half as tariff-related pricing was lapped. The U.S. dental market remains soft, with elective categories like ortho and implants running below historical trends.

The forward picture turns on China VBP, and the timeline has slipped. Last quarter, management expected VBP to conclude in the second half of 2026 with China growing again. Now results are expected in mid-December, implementation likely comes in the first half of 2027, and the Q4 channel rebound is off the table. The price cuts are steep:

• **Ortho:** roughly 50% on about 3% of sales.
• **Implants:** 10-15%.

Management still frames VBP as net growth-positive in 2027 and explicitly guided to further gross and EBITDA margin expansion next year despite the cuts. That is an assertive commitment, and it will be tested. The narrowed 3.75%-4.25% core growth range implies a slightly negative fourth quarter, partly reflecting four fewer selling days. A stronger dollar should also shave about a point from reported Q4 growth. Offsets include Spark clear aligners growing high single digits with a fresh Japan launch, share gains in diagnostics, and new product launches. The Versa acquisition is tracking ahead of plan, and management raised the possibility of a larger challenger-implant deal, backed by 0.6x leverage. Buybacks, however, shrank to about $10 million from roughly 2.4 million shares repurchased in Q2.

The market had already been leaning toward the deceleration story. Shares closed at $24.77 ahead of the report, down 13.7% from the $28.70 open after the August release. They were 3.7% below the 200-day moving average of $25.73. The stock peaked at $29.00 in mid-August, fell to $22.20 on October 13, and has since recovered about 11.6% off that low, leaving it in the lower-middle of its inter-earnings range. Investor sentiment stayed mildly positive but softened slightly, to 0.137 from 0.167, a modest erosion rather than a sharp turn. The Earnings Whispers trend readings are mixed: momentum is positive, while price and AVWAP remain negative.

The bottom line is that Envista continues to convert modest sales into outsized earnings gains through cost discipline, and the raised guidance shows that playbook still works. But core growth has decelerated for four straight quarters. China recovery has been pushed into 2027 alongside meaningful price cuts, and Q4 is guided roughly flat to down on a core basis. Bulls have a credible margin story and a management team willing to commit to 2027 expansion. Bears have legitimate ammunition in a top line that is losing altitude. Until core growth stabilizes, the beat-and-raise pattern may carry less weight with investors than it has earlier this year.